MoneyWorks4Me

Lupin rises on getting USFDA approval for its Daysee Tablets

15 Apr 2013 Evaluate

Lupin is currently trading at Rs. 665.50, up by 5.85 points or 0.89% from its previous closing of Rs. 659.65 on the BSE.

The scrip opened at Rs. 654.50 and has touched a high and low of Rs. 668.70 and Rs. 654.50 respectively. So far 6,390 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 668.70 on 15-Apr-2013 and a 52 week low of Rs. 507.00 on 15-Jun-2012.

The current market cap of the company is Rs. 29,774.00 crore.

The promoters holding in the company stood at 46.84%, while Institutions and Non-Institutions held 43.13% and 10.04% respectively.

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Daysee Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharm.’s Seasonique Tablets.

Lupin’s Daysee Tablets is indicated for use by women to prevent pregnancy. The total sales for Branded and generic sales for the product stood at $161 million (IMS MAT Dec 2012). Lupin has already commenced shipping the product.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2243.05 23.05 (1.04%)
20-Aug-2026 09:10 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1910.00
Dr. Reddys Labs. 1171.75
Cipla 1443.60
Lupin 2243.05
Zydus Lifesciences 1112.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: